These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
541 related articles for article (PubMed ID: 24493994)
1. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Lagacé-Wiens P; Walkty A; Karlowsky JA Core Evid; 2014; 9():13-25. PubMed ID: 24493994 [TBL] [Abstract][Full Text] [Related]
6. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Shirley M Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219 [TBL] [Abstract][Full Text] [Related]
7. Ceftazidime/Avibactam: Who Says You Can't Teach an Old Drug New Tricks? Barber KE; Ortwine JK; Akins RL J Pharm Pharm Sci; 2016; 19(4):448-464. PubMed ID: 28057163 [TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460 [TBL] [Abstract][Full Text] [Related]
9. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
10. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases. Meschiari M; Asquier-Khati A; Tiseo G; Luque-Paz D; Murri R; Boutoille D; Falcone M; Mussini C; Tattevin P; Int J Antimicrob Agents; 2024 Jul; 64(1):107186. PubMed ID: 38688353 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme. Torres A; Wible M; Tawadrous M; Irani P; Stone GG; Quintana A; Debabov D; Burroughs M; Bradford PA; Kollef M J Antimicrob Chemother; 2023 Nov; 78(11):2672-2682. PubMed ID: 37700689 [TBL] [Abstract][Full Text] [Related]
12. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Liscio JL; Mahoney MV; Hirsch EB Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591 [TBL] [Abstract][Full Text] [Related]
13. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae. Santevecchi BA; Smith TT; MacVane SH Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227 [TBL] [Abstract][Full Text] [Related]
14. Stone GG; Newell P; Bradford PA Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686147 [TBL] [Abstract][Full Text] [Related]
15. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893 [TBL] [Abstract][Full Text] [Related]
16. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Mawal Y; Critchley IA; Riccobene TA; Talley AK Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. Sader HS; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649 [TBL] [Abstract][Full Text] [Related]
18. Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Daikos GL; da Cunha CA; Rossolini GM; Stone GG; Baillon-Plot N; Tawadrous M; Irani P Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572708 [No Abstract] [Full Text] [Related]
19. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909 [TBL] [Abstract][Full Text] [Related]
20. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. van Duin D; Bonomo RA Clin Infect Dis; 2016 Jul; 63(2):234-41. PubMed ID: 27098166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]